ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
20 Septembre 2023 - 1:15PM
Business Wire
Solution seamlessly delivers proprietary
technology, real world data and analytics, aligning to industry
security and data privacy standards
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence
and clinical research organisation, today announces the release of
its next generation Clinical Trial Tokenisation solution. The
combination of ICON’s proprietary tokenisation engine, access to
real-world data and advanced clinical analytics expertise, now
delivered through a cohesive and seamless operational model,
provides valuable, long-term insights on drug safety and efficacy,
throughout the product development lifecycle.
ICON’s next generation proprietary Clinical Trial Tokenisation
solution seamlessly integrates all the necessary components to
allow for the collation of patient data in a consented, discreet
and non-intrusive way with Privacy Protected Record Linkage (PPRL)
across time and source. Furthermore, ICON’s capability to generate
multiple tokens, coupled with advanced analytics, provides highly
accurate matching (up to ~90%) of clinical trial participants to
the largest ecosystem of real-world data sources in the United
States. This enables the best available secondary data to be used,
resulting in enhanced evidence generation in a highly cost and time
efficient manner for our customers, with robust protection of
patient privacy.
Valuable insights from this offering can be leveraged in many
ways, including regulatory and reimbursement discussions and
scientific publications to optimise clinical development
lifecycles. This can also be used to better understand the response
of specific sub-cohorts of patients, and to conduct long-term
safety surveillance.
ICON’s Clinical Trial Tokenisation solution is delivered within
an operating framework aligned to industry security and data
privacy standards, and its corporate security and data protection
programs have been assessed to ISO 27001 and 27701 standards.
Steve Cutler, CEO, ICON commented: “As an early pioneer of
clinical trial tokenisation, ICON fully understands the potential
it has to transform clinical development. This enhanced integrated
offering enables customers to leverage powerful analytics in an
efficient and cost-effective manner for greater understanding and
insights of trends in disease, indication and treatment patterns
that will support better decision making at every stage of the
product lifecycle.”
ICON is uniquely positioned to support customers because, in
addition to commercialisation capability, it has extensive
experience in clinical research, regulatory management, and
healthcare intelligence, all crucial to clinical trial
tokenisation.
Further information on this enhanced offering can be found at
ICONplc.com/tokenisation and ICONplc.com/digital-platform.
Ends
This press release contains forward-looking statements,
including statements about our financial guidance. These statements
are based on management's current expectations and information
currently available, including current economic and industry
conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
F-4, S-8, F-3 and certain other reports, which are available on the
SEC's website at http://www.sec.gov.
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. We develop new innovations, drive emerging therapies
forward and improve patient lives. With headquarters in Dublin,
Ireland, ICON employed approximately 41,160 employees in 108
locations in 53 countries as at June 30, 2023. For further
information about ICON, visit www.iconplc.com.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230920888786/en/
Claire Quinn (GMT time zone) Corporate Communications, ICON plc
claire.quinn@iconplc.com +353 87 4066091
Weber Shandwick (PR adviser) Lisa Henry (GMT time zone) +447785
458203 lhenry@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024